Trial to Evaluate Fecobionics in Fecal Incontinence (FI) (NORMAL and ABNORMAL-FI)
Primary Purpose
Normal Subjects, Fecal Incontinence
Status
Recruiting
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
Fecobionics
Sponsored by
About this trial
This is an interventional basic science trial for Normal Subjects focused on measuring anorectal, Fecobionics, defecation
Eligibility Criteria
Inclusion Criteria:
- Subject must provide written informed consent;
- Willing and able to undergo required study tests, surveys, and procedures;
- Age > 18 and < 75 years of age.
Exclusion Criteria:
- Female who is pregnant;
- Prior anorectal surgery;
- Prior bowel resection;
- History of chronic constipation;
- In the opinion of the investigator, the subject is not a suitable candidate for the study.
Sites / Locations
- California Medical Innovations Institute
- Augusta University Medical CenterRecruiting
Arms of the Study
Arm 1
Arm Type
Experimental
Arm Label
Fecobionics study
Arm Description
Fecobionics
Outcomes
Primary Outcome Measures
Length-tension properties of the anal sphincter will be reported
Front-rear pressure difference (in cmH2O) will be measured
Fecobionics contain pressure sensors in front end and rear end which can measure pressures
Secondary Outcome Measures
Anorectal angle (in degree) will be measured
Fecobionics contain motion processing units with gyroscopes and accelerometers, which can measure angles
Expulsion velocity (in mm/s) will be reported
Full Information
NCT ID
NCT05412069
First Posted
May 31, 2022
Last Updated
March 2, 2023
Sponsor
The California Medical Innovations Institute, Inc.
Collaborators
Augusta University Medical Center
1. Study Identification
Unique Protocol Identification Number
NCT05412069
Brief Title
Trial to Evaluate Fecobionics in Fecal Incontinence (FI) (NORMAL and ABNORMAL-FI)
Official Title
A Multicenter, Prospective, Non-randomized Study on Pathophysiology, Diagnosis, and Biofeedback Therapy in Fecal Incontinence (FI) Using Fecobionics (NORMAL and ABNORMAL-FI)
Study Type
Interventional
2. Study Status
Record Verification Date
March 2023
Overall Recruitment Status
Recruiting
Study Start Date
February 15, 2023 (Actual)
Primary Completion Date
December 1, 2024 (Anticipated)
Study Completion Date
December 31, 2024 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
The California Medical Innovations Institute, Inc.
Collaborators
Augusta University Medical Center
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
The objective is to determine the length-tension properties of the anal sphincters using Fecobionics in normal subjects and FI patients during anal distension and during simulated evacuation. Fecobionics has the consistency and shape of normal stool and can record pressures, cross-sectional area, orientation and viscoelastic properties of the anorectum and can map the geometric profiles during evacuation, and thereby provides multi-dimensional measurements of pressures, deformability, and topographic changes. Fecobionics combines several existing tests to provide novel insight into anorectal function. The purpose for the development was to overcome the technological controversies and disagreement between various tests and unphysiological test conditions. The aim was to imitate defecation as much as possible to the natural process. Fecobionics was developed to simulate stool and to provide the driving pressure and resulting deformations of stool along with a measure of an objective anorectal angle during defecation in a single examination. Fecobionics makes it possible to describe objectively, without disturbing the defecation process, the opening characteristics and pressure signatures during initial entry into the relaxing anal canal.
The overall goal is to provide mechanistic understanding of defecation in health and defecatory disorders. It exceeds previous attempts to make artificial stool for evaluation of defecation (BET and FECOM) and integrates other technologies as well. It was designed to have a consistency and deformability of Type 4 (range type 3-5) on the Bristol stool form scale. The range from types 3-5 is found in 70% of normal subjects. A major novelty is that Fecobionics measures pressures in axial direction; i.e., in the flow direction.
Detailed Description
Defecatory disorders affect 25% of the population and the incidence is rising. These diseases pose a major health care burden and are poorly recognized and treated. The need for better diagnostics and therapeutics is substantial. Defecatory disorders including constipation and fecal incontinence are associated with diet, aging and a variety of underlying factors and diseases.
Current diagnostic tests such as the balloon expulsion test (BET), high-resolution anorectal manometry (HRM), defecography, and dynamic pelvic MRI are indirect surrogates for the act of defecation, and provide incomplete and often conflicting information, because most of them are not simulating defecation. Most tests are done with the subjects in lateral lying position, which is an abnormal posture for defecation. The results of these tests correlate poorly with symptoms and treatment outcomes. The simplest anorectal physiology test is the BET where a rectal balloon is filled with 50 ml water where expulsion within 1-2 min is considered normal. Anorectal manometry records the pressure exerted by the anal sphincters and puborectalis during rest and contraction. Defecography shows how well the rectum holds and evacuates the stool. Defecography uses a liquid with mechanical properties that are quite dissimilar to feces and hence cannot represent the physiology of defecation. Current research paradigms for defecatory disorders need a new technology that can provide real time, quantitative, and mechanistic insights by simulating defecation physiologically through multi-dimensional measurements of the pressure profiles, deformability, and topographic changes. The investigators have developed a wired Fecobionics device that integrates current tests to provide detailed mapping of physiological parameters during defecation of the device. This device has been further developed to a wireless device with expanded measurements. This was tested in the NORMAL study.
In this study, the investigators would like to learn more about FI patients and obtain ultrasonography data from 15 normal subjects for comparison. Fecal incontinence is a common problem, often nor properly diagnosed and treated. The goals are to determine the role of anorectal muscles in maintaining continence and defecation, and how their malfunction(s) can cause FI by using the new technology (i.e., Fecobionics) and novel methodology. Specifically, the investigators wish to determine the anal length-tension properties, a measure of the active and passive properties of the anal sphincter muscles, i.e. the compliance or stiffness.
Fecal incontinence (FI) affects 1 in 7 Americans with a rising incidence that poses a major healthcare burden. FI pathophysiology is poorly understood and consequently there is a dearth of effective treatment(s) compared to other defecatory disorders including constipation. A critical barrier to progress has been the lack of comprehensive, physiologically relevant and practical diagnostic test for identifying underlying mechanism(s). Current tests provide either incomplete or conflicting information that do not correlate with symptoms and treatment outcomes. The objective is to determine the role of anorectal muscles in maintaining continence and facilitating defecation, and how their malfunction(s) can cause FI by using a novel technology called Fecobionics (an electronic simulated stool) to evaluate the diagnostic and therapeutic utility of the novel technology. Fecobionics has the consistency and shape of normal stool and can record pressures, cross-sectional area, orientation and viscoelastic properties of the anorectum and can map the geometric profiles during evacuation, and thereby provides multi-dimensional measurements of pressures, deformability, and topographic changes. The central hypothesis is that the movement of the Fecobionics device through the anorectum will provide unknown and new mechanistic insights on anorectal physiology including length-tension properties of anorectal muscles, intraluminal pressure changes, deformability, and resistance generated during its movement and distensibility of the anal sphincters in NS and FI patients. Fecobionics studies have been done on more than 100 normal subjects and patients with anorectal disorders in Hong Kong using a structurally similar but simplified wired device that merely measured pressures. The published Fecobionics studies revealed clear differences between normal subjects and FI patients, as well as they demonstrated that the correlation with symptoms are higher with Fecobionics than with current technology (HRM-BET) and the outcome of biofeedback therapy can be predicted with Fecobionics. In this study, the Fecobionics upgraded hardware, software and graphical user interface (GUI) will be used to generate clinical data in FI patients and in later stages it will be used to guide biofeedback training (BT) in FI patients. Whether specific muscle length-tension properties, i.e., the relationship between muscle length and the force the anorectal muscle produces at that length, play a role in the evacuation and continence mechanics in NS and FI patients has not been studied in detail, and until now an appropriate method and system for such an analysis has not been available. The approach is based on promising data using 1) Anal EndoFLIP, 2) the previous wired Fecobionics prototype device (both invented by the PI) and 3) 3D ultrasound with vaginal distension for determining puborectalis length-tension properties, all of which have suggested that these properties are important. The overall objective is to validate a fully integrative dynamic investigational tool that mimics a normal stool for diagnostics and FI treatment. The expected outcomes are that the device will provide new mechanistic insights on anorectal physiology including the contributions of muscle length-tension properties, and facilitate development of new FI treatment strategies including improvement of BT.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Normal Subjects, Fecal Incontinence
Keywords
anorectal, Fecobionics, defecation
7. Study Design
Primary Purpose
Basic Science
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
155 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
Fecobionics study
Arm Type
Experimental
Arm Description
Fecobionics
Intervention Type
Device
Intervention Name(s)
Fecobionics
Other Intervention Name(s)
anorectal manometry, balloon expulsion test, anal ultrasonography
Intervention Description
Fecobionics is a novel device to be inserted through the anal canal into rectum for studying defecation. Anorectal manometry, balloon expulsion test, and anal ultrasonography will be used as reference.
Primary Outcome Measure Information:
Title
Length-tension properties of the anal sphincter will be reported
Time Frame
1.5 year
Title
Front-rear pressure difference (in cmH2O) will be measured
Description
Fecobionics contain pressure sensors in front end and rear end which can measure pressures
Time Frame
1.5 year
Secondary Outcome Measure Information:
Title
Anorectal angle (in degree) will be measured
Description
Fecobionics contain motion processing units with gyroscopes and accelerometers, which can measure angles
Time Frame
1.5 year
Title
Expulsion velocity (in mm/s) will be reported
Time Frame
1.5 year
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria:
Subject must provide written informed consent;
Willing and able to undergo required study tests, surveys, and procedures;
Age > 18 years of age.
Exclusion Criteria:
Female who is pregnant;
Prior anorectal surgery;
Prior bowel resection;
History of chronic constipation;
In the opinion of the investigator, the subject is not a suitable candidate for the study.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Hans Gregersen, MD, PhD
Phone
8582497400
Email
hag@giome.org
First Name & Middle Initial & Last Name or Official Title & Degree
Satish Rao, MD, PhD
Phone
7067212238
Email
srao@augusta.edu
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Hans Gregersen, MD, PhD
Organizational Affiliation
California Medical Innovations Institute
Official's Role
Principal Investigator
Facility Information:
Facility Name
California Medical Innovations Institute
City
San Diego
State/Province
California
ZIP/Postal Code
92121
Country
United States
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Hans Gregersen, PhD
Phone
858-249-7400
Email
hag@giome.org
First Name & Middle Initial & Last Name & Degree
Ghassan Kassab, PhD
Phone
8582497400
Email
gkassab@calmi2.org
First Name & Middle Initial & Last Name & Degree
Yanmin Wang, MD, PhD
Facility Name
Augusta University Medical Center
City
Augusta
State/Province
Georgia
ZIP/Postal Code
30912
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Satish Rao, MD, PhD
Phone
706-721-2238
Email
srao@augusta.edu
First Name & Middle Initial & Last Name & Degree
Tennekoon Karunaratne, MD, PhD
Phone
7067211968
Email
tkarunaratne@augusta.edu
12. IPD Sharing Statement
Learn more about this trial
Trial to Evaluate Fecobionics in Fecal Incontinence (FI) (NORMAL and ABNORMAL-FI)
We'll reach out to this number within 24 hrs